HerediGENE is a test that fully analyzes a panel of genes, including BRCA1 and BRCA2, which are associated with increased risk of developing breast, ovarian and other hereditary cancers.
Mo.Re. (Molecular Response) is a multi-gene assay developed to provide an insight to the tumor’s biology of each patient.
Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.
Com.Pl.i.t DX is a multigene test designed to help you and your physician make informed treatment decisions based on the unique biology of your tumor and individualize your treatment.
Com.Pl.i.t DX Liquid is a genomic test in a single blood sample for cancer treatment decisions as an alternative for tumor biopsy.
Microsatellite Instability (MSI) is a condition that appears on the DNA of specific cells (such as cancer cells) where the number of microsatellites (short repeats of DNA sequences) in these cells, is different from the repeats that existed in the DNA when it was inherited.
The PD-L1 test helps doctors determine whether a patient is likely to benefit from cancer drugs known as immune checkpoint inhibitors such as KEYTRUDA®.
PCA3 is a non-invasive test for the detection of prostate cancer, highly specific and more precise than all other available screening tests for prostate cancer and is performed on a simple urine sample.
In Genekor, we offer Single Gene analysis with the highest quality, using the most advanced technology available.
Genekor is a Molecular Biology Laboratory, focused in Oncology. Our journey began in 2007 and we constantly grow in order to provide the highest quality services in the Molecular Oncology sector. A passionate team sharing the same vision on quality healthcare and molecular oncology is working together in order to provide patients and physicians with actionable information.
Genekor’s highly experienced scientific and management team are cooperating passionately in order to provide the physicians and patients with the highest quality services in oncology. This is us.